Stoke Therapeutics has announced encouraging results from its Phase I/IIa clinical trial for a treatment candidate, STK-001, for Dravet syndrome.

Viking Therapeutics has announced positive results from a Phase I clinical trial of VK2735, an oral medication for obesity.

FSD Pharma has announced the initiation of a Phase 1 clinical trial for a novel compound, Lucid-21-302, intended to treat multiple sclerosis (MS).

Cantargia a drug under investigation for use in treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Sagimet Biosciences a drug candidate aimed at treating metabolic dysfunction-associated steatohepatitis (MASH).

Iambic Therapeutics has dosed the first patient in a Phase 1 clinical trial for IAM1363.

This is a phase 1b/2a study that evaluates the safety and efficacy of Pexa-Vec, a modified vaccinia virus, when used alongside cemiplimab, an anti-PD-1 monoclonal antibody from Regeneron Pharmaceuticals Inc.

Immuneering Corporation, a clinical-stage oncology firm, has initiated a Phase 1/2a clinical trial for IMM-6-415, a novel Deep Cyclic Inhibitor (DCI) targeting the MAPK pathway.

AFM24 Clinical Trial Updates: In a Phase 1/2a study combining AFM24 with atezolizumab for non-small cell lung cancer (NSCLC) patients with EGFR-wildtype.

The preliminary safety findings from a Phase 1B clinical trial involving VRON-0200, a groundbreaking immunotherapy for chronic hepatitis B (HBV), were recently highlighted.

In a recent phase 1b clinical trial, patients received multiple injections of a novel immunotherapy, CAN-3110, developed by Candel Therapeutics.

MapLight Therapeutics has initiated a Phase 1 clinical trial for ML-007/PAC, a novel combination therapy aimed at treating schizophrenia and Alzheimer's disease psychosis.